Novel polyethylene glycol (PEG)-drug conjugate of Venetoclax, a Bcl-2 inhibitor, for treatment of acute myeloid leukemia (AML)

Novel Potent PD-L1 Inhibitor (IC50 1.8 nM), binding to human PD-L1 (hPD-L1) with a KD value of 3.34 nM, without showing any binding to hPD-1, blocking PD-1/PD-L1 interaction with an EC50 value of 375 nM

Novel PROTAC dual inhibitor and degrader of PD-L1, inhibiting PD-1/PD-L1 interaction with IC50 of 39.2 nM in an HTRF binding assay

Novel PD-L1 degrader, showing 66.99% degradation activity at 20 μM with no calcium blocking effect, strengthening the T cell-mediated killing of tumor cells

Protein disulfide isomerase (PDI) inhibitor

Novel Peptide Deformylase (PDF) Inhibitor

Novel inhibitor of melanogenesis

Novel Potent, Selective, and Orally Bioavailable Inhibitor against Phosphodiesterase-9 (PDE9)

Novel selective PDE9 inhibitor with strong antioxidant activity, inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer’s disease

Novel cell-permeable PDE7 inhibitor, targeting the cyclic adenosine monophosphate (cAMP)/cAMP-response element binding protein (CREB) pathway, exerting neuroprotection in an Alzheimer's disease (AD) model

Potent and selective second-generation phosphodiesterase type 5 (PDE5) inhibitor

Novel G6PD inhibitor

Novel inducer of mitotic arrest and apoptosis in human progenitor and cancer cells

Novel selective inhibitor of STAT3 phosphorylation, binding to the SH2 domain of STAT3, exhibiting remarkable antiproliferative activity against three cancer cell lines (HCT-116, SW480 and MDA-MB-231)

Novel cell specific photoswitchable agonist for reversible control of endogenous dopamine receptors

Novel, potent, and selective NR1/2B NMDA receptor antagonist

AMPA receptor antagonist

AMPA receptor antagonist

Neuropeptide Y Y1 receptor antagonist

Selective antagonist for human ETA receptors

Selective D3 dopamine receptor agonist

Novel potent programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitor (IC50 9.1 nM)

Novel inhibitor of PD-1/PD-L1 (IC 50 value of 56.58 nM), dose-dependently promoting HepG2 cell death in a co-culture model of HepG2/hPD-L1 and Jurkat T cells, effectively inhibiting tumor growth (TGI of 76.4% at 90 mg/kg) in an immune checkpoint humanized

Novel Potent Inhibitor of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

Novel bifunctional inhibitor of PD-1/PD-L1 interactions, promoting dimerization, internalization, and degradation of PD-L1, suppressing tumor growth in vivo by activating antitumor immunity

Novel potent PD-1/PD-L1 antagonist (IC50 of 16.17 nM), activating the antitumor immunity of T cells efficiently in PBMCs

Novel inhibitor of PD-I/PD-L1 interaction to be used as a negative immune checkpoint regulatory and antineoplastic agent

Novel liver-targeted inhibitor of ribosomal synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9)

Novel PCSK9 mRNA translation inhibitor

Novel PCSK9 mRNA translation inhibitor